Tempest Therapeutics (TPST) Return on Capital Employed (2012 - 2026)
Tempest Therapeutics (TPST) posted Return on Capital Employed of 193.76% for Q4 2025, up 8.05% sequentially from 210.73% in Q3 2025, and down 1449.0% YoY from 14.36% in Q4 2024.
Tempest Therapeutics (TPST) Return on Capital Employed (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Return on Capital Employed for 14 years, with the latest figure at 193.76% in Q4 2025.
- Quarterly Return on Capital Employed fell 1449.0% year-over-year to 193.76% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 193.76% (down 1449.0% YoY) and the FY2025 annual result came in at 102.62%, up 2738.0% from the prior year.
- Return on Capital Employed grew to 193.76% in Q4 2025 per TPST's latest filing, from 210.73% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 53.8% in Q4 2021 and troughed at 210.73% in Q3 2025.
- A 5-year average of 120.99% and a median of 106.49% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2021 and 2025: Return on Capital Employed jumped 18149 bps in 2021, then slumped 11100 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 53.8% in 2021, then slumped by 36 bps to 73.15% in 2022, then slumped by 40 bps to 102.72% in 2023, then sank by 75 bps to 179.27% in 2024, then decreased by 8 bps to 193.76% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 193.76%, 210.73%, and 204.74% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | -236.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -236.53% |
| Dec 31, 2025 | -193.76% |
| Sep 30, 2025 | -210.73% |
| Jun 30, 2025 | -204.74% |
| Mar 31, 2025 | -190.23% |
| Dec 31, 2024 | -179.27% |
| Sep 30, 2024 | -148.24% |
| Jun 30, 2024 | -110.26% |
| Mar 31, 2024 | -79.22% |
| Dec 31, 2023 | -102.72% |
| Sep 30, 2023 | -153.33% |
| Jun 30, 2023 | -128.97% |
| Mar 31, 2023 | -99.60% |
| Dec 31, 2022 | -73.15% |
| Sep 30, 2022 | -76.49% |
| Jun 30, 2022 | -68.50% |
| Mar 31, 2022 | -60.92% |
| Dec 31, 2021 | -53.80% |
| Sep 30, 2021 | -82.81% |
| Jun 30, 2021 | -63.11% |